HEMOSTEMIX INC.
About Hemostemix Inc.:
Hemostemix Inc. (TSXV: HEM; OTCQB:HMTXF) (“Hemostemix” or the “Company”) is an autologous (patient’s own) stem cell company with a promising break through treatment for ischemia (ischemic cardiomyopathy, angina, peripheral arterial disease including chronic limb threatening ischemia (“CLTI”)).
Hemostemix’s patented technology is based on more than 15 years of clinical data demonstrating the ability of our patient’s cell product to regenerate diseased and damaged ischemic tissue and organs.
The Company, in partnership with manufacturing partner CytoImmune's engineering team, is advancing Hemostemix's patented Automated Cell Therapy System (ACTS). This robotics-based manufacturing platform is designed to produce up to 2,880 ACP-01 therapies annually per 10' x 10' clean room. Scaled to 10 production cells operating at 80% efficiency, the system could deliver up to 23,040 ACP-01 therapies annually, each priced at $50,000. This would generate cash flow of up to $96,000,000/month
ACP-01 (“ACP”), our lead clinical stage candidate, like NCP-01 and CCP-01, is generated from the patient’s own blood with a short production time.
Exchange: TSXV
Symbol: HEM
Current Share Price: $0.35 (Jan 23, 2025)
Corporate Structure: (as at Jan 10, 2025)
Recent News Releases:
January 23, 2025 - Hemostemix Up-Lists to OTCQB While it Presents its Global Scale-Up Strategy at Two Investor Conferences in Puerto Rico
January 20, 2025 - Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact
January 13, 2025 - Hemostemix Announces Settlement via Depository Trust Company plus OTCQB Update
January 9, 2025 - Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up
January 6, 2025 - Hemostemix Announces the Incorporation of Hemostemix PR Inc.: 50 % Reimbursement of R&D Expenses in Cash
January 2, 2025 - Hemostemix is Up-listing in the USA to Generate Liquidity
December 31, 2024 - Hemostemix’s Social Media Awareness of “Your Fountain of Youth” (TM) Regenerative Medicine Treatments is Gaining Traction
December 17, 2024 - Hemostemix Drives Social Media Awareness of Its Regenerative Medicine Treatments
November 29, 2024 - Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258
November 25, 2024 - Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway
October 31, 2024 - Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement
October 11, 2024 - Hemostemix Announces Private Placement
August 1, 2024 - Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
June 11, 2024 - Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
June 3, 2024 - Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
March 7, 2024 - Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
February 6, 2024 - Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
Company Highlights:
ACP is a break-through treatment for no-option angina, dilated and ischemic cardiomyopathy and CLTI.
ACP is effective, and, because it is sourced from the patient's own blood and cultured in the patient's serum, it is completely autologous and therefore safe in the short and long term.
ACP is protected by 91 patents and is globally scalable. The production team has more than 20 years of stem cell experience.
Published three studies, each in a peer reviewed journal, which indicated improved heart function by up to 27%.
Saved 93.5% of limbs from amputation in phase II trial.
498 patients treated, 7 studies, including a phase II trial, demonstrate ACP is safe and effective.
Over $40 million invested in technology over 15 years of development (management and board have invested $8.75 million).
The Company has filed for orphan disease status for Dilated Cardiomyopathy. Once status is granted, it provides 7 years exclusivity, fee abatement, and grant funding opportunities.
ACP addresses two very large markets that are comprised of significant unmet needs
Canadian Institute of Health Information (““CIHI”) estimates that hospitalizations related to CLTI amputation account for over $750 million in health-care costs per year in Canada - Click here to read the September 28, 2024 National Post article discussing the CIHI Report
In August 2024, Hemostemix signed a binding and definitive Manufacturing Services Agreement with CytoImmune Therapuetics (“CytoImmune”) that re-establishes production of ACP-01 at CytoImmune’s state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico. This Agreement provides the Company with a renewable two-year fixed cost, high margin, product to sell globally.
Hemostemix, in partnership with manufacturing partner CytoImmune's engineering team, is advancing its patented Automated Cell Therapy System (ACTS). This robotics-based manufacturing platform is designed to produce up to 2,880 ACP-01 therapies annually per 10' x 10' clean room. Scaled to 10 production cells operating at 80% efficiency, the system could deliver up to 23,040 ACP-01 therapies annually, each priced at $50,000. This would generate cash flow of up to $96,000,000/month
ACT 60 (Puerto Rico legislation) generates 50% cash back of all R&D, a 15-year 4% profit tax, and a 20% tax credit for offshore expenses.
Significant revenue at high margin (up to 80+%) from scalable compassionate treatments in 2025 and clinical trials
The Company expects to be cashflow positive by late 2025.